[go: up one dir, main page]

WO2002009750A3 - Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene - Google Patents

Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene Download PDF

Info

Publication number
WO2002009750A3
WO2002009750A3 PCT/US2001/023612 US0123612W WO0209750A3 WO 2002009750 A3 WO2002009750 A3 WO 2002009750A3 US 0123612 W US0123612 W US 0123612W WO 0209750 A3 WO0209750 A3 WO 0209750A3
Authority
WO
WIPO (PCT)
Prior art keywords
ehv
isolates
present
vaccines
herpesvirus type
Prior art date
Application number
PCT/US2001/023612
Other languages
French (fr)
Other versions
WO2002009750A2 (en
Inventor
Dennis J O'callaghan
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Priority to DE2001961753 priority Critical patent/DE01961753T1/en
Priority to NZ523772A priority patent/NZ523772A/en
Priority to EP01961753A priority patent/EP1317481A2/en
Priority to CA 2417340 priority patent/CA2417340A1/en
Priority to JP2002515303A priority patent/JP2004512826A/en
Priority to AU2001282997A priority patent/AU2001282997A1/en
Priority to MXPA03000823A priority patent/MXPA03000823A/en
Publication of WO2002009750A2 publication Critical patent/WO2002009750A2/en
Publication of WO2002009750A3 publication Critical patent/WO2002009750A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention relates to mutant Equine herpesvirus type-1 (EHV-1) isolates, and in particular, EHV-1 isolates carrying mutations in the immediate-early (IE) gene of the viral genome. A panel of EHV-1 mutant isolates have been described. Preffered EHV-1 isolates are those which are replication-competent and nonpathogenic. The mutant EHV-1 isolates of the present invention are useful in formulating vaccine compositions for preventing and treating EHV-1 infections in horses. The present invention further provides methods of determining the pathogenicity of an EHV-1 virus present in a horse subject which has been previously immunized with a non-pathogenic EHV-1 isolate of the present invention.
PCT/US2001/023612 2000-07-27 2001-07-27 Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene WO2002009750A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE2001961753 DE01961753T1 (en) 2000-07-27 2001-07-27 VACCINE AGAINST HORSE HERPESVIRUS-1: VIRUSES WITH MUTATIONS WITHIN THE "IMMEDIATE-EARLY" GENE
NZ523772A NZ523772A (en) 2000-07-27 2001-07-27 Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene
EP01961753A EP1317481A2 (en) 2000-07-27 2001-07-27 Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene
CA 2417340 CA2417340A1 (en) 2000-07-27 2001-07-27 Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene
JP2002515303A JP2004512826A (en) 2000-07-27 2001-07-27 Vaccine against equine herpesvirus 1: a virus with a mutation in the immediate early gene
AU2001282997A AU2001282997A1 (en) 2000-07-27 2001-07-27 Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene
MXPA03000823A MXPA03000823A (en) 2000-07-27 2001-07-27 Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62674800A 2000-07-27 2000-07-27
US09/626,748 2000-07-27

Publications (2)

Publication Number Publication Date
WO2002009750A2 WO2002009750A2 (en) 2002-02-07
WO2002009750A3 true WO2002009750A3 (en) 2003-03-27

Family

ID=24511676

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/023612 WO2002009750A2 (en) 2000-07-27 2001-07-27 Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene

Country Status (9)

Country Link
EP (1) EP1317481A2 (en)
JP (1) JP2004512826A (en)
AR (1) AR031599A1 (en)
AU (1) AU2001282997A1 (en)
CA (1) CA2417340A1 (en)
DE (1) DE01961753T1 (en)
MX (1) MXPA03000823A (en)
NZ (1) NZ523772A (en)
WO (1) WO2002009750A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1129722A1 (en) 2000-02-17 2001-09-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-mutants
AR040601A1 (en) 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed GM NEGATIVE EHV MUTANTS WITHOUT HETEROLOGICAL ELEMENTS
AU2003251356A1 (en) * 2002-07-26 2004-02-16 Animal Health Trust Viral marker
BR112014023414B1 (en) * 2012-03-20 2022-08-30 Boehringer Ingelheim Animal Health USA Inc. RECOMBINANT EQUINE HERPESVIRUS-1 VACCINE CONTAINING A MUTANT C GLYCOPROTEIN AND ITS USES
CN108315487B (en) * 2018-04-16 2021-06-22 福建省农业科学院生物技术研究所 Primer group and kit for detecting eel herpesvirus and application of primer group and kit
CN110885794A (en) * 2019-10-30 2020-03-17 新疆农业大学 Equine herpesvirus type 1 and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0668355A1 (en) * 1993-12-20 1995-08-23 Akzo Nobel N.V. Vaccine for the protection of horses against equine herpesvirus infection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292653A (en) * 1989-09-27 1994-03-08 Novagene, Inc. Equine herpesvirus 1 tk mutants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0668355A1 (en) * 1993-12-20 1995-08-23 Akzo Nobel N.V. Vaccine for the protection of horses against equine herpesvirus infection

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
(1999) 224 PP. AVAIL.: UMI, ORDER NO. DA9942077 FROM: DISS. ABSTR. INT., B 2000, 60(8), 3715 *
BUCZYNSKI KIMBERLY A ET AL: "Characterization of the transactivation domain of the equine herpesvirus type 1 immediate-early protein.", VIRUS RESEARCH, vol. 65, no. 2, 15 December 1999 (1999-12-15), pages 131 - 140, XP002221714, ISSN: 0168-1702 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1999, BUCZYNSKI, KIMBERLY ANN: "Characterization of equine herpesvirus 1 harboring mutant forms of the immediate - early protein", XP002221717, retrieved from STN Database accession no. 132:234179 HCA *
GARKO-BUCZYNSKI KIMBERLY ET AL: "Complementation of a replication-defective mutant of equine herpesvirus type 1 by a cell line expressing the immediate-early protein.", VIROLOGY, vol. 248, no. 1, 15 August 1998 (1998-08-15), pages 83 - 94, XP002221715, ISSN: 0042-6822 *
See also references of EP1317481A2 *
SMITH PATRICK M ET AL: "Characterization of the cytolytic T-lymphocyte response to a candidate vaccine strain of equine herpesvirus 1 in CBA mice.", JOURNAL OF VIROLOGY, vol. 72, no. 7, July 1998 (1998-07-01), pages 5366 - 5372, XP002221716, ISSN: 0022-538X *

Also Published As

Publication number Publication date
WO2002009750A2 (en) 2002-02-07
MXPA03000823A (en) 2003-09-10
AU2001282997A1 (en) 2002-02-13
JP2004512826A (en) 2004-04-30
EP1317481A2 (en) 2003-06-11
AR031599A1 (en) 2003-09-24
CA2417340A1 (en) 2002-02-07
DE01961753T1 (en) 2004-03-11
NZ523772A (en) 2004-06-25

Similar Documents

Publication Publication Date Title
Kalantari-Dehaghi et al. Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling
WO2003092592A3 (en) Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
Chalmers et al. Efficacy of feline panleucopenia vaccine to prevent infection with an isolate of CPV2b obtained from a cat
YU37502A (en) Infectious clones
Ikegame et al. Qualitatively distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants
WO2003023040A3 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
Nuñez et al. SARS-CoV-2 B. 1.1. 7 infection of syrian hamster does not cause more severe disease, and naturally acquired immunity confers protection
Liu et al. A bovine herpesvirus type 1 mutant virus specifying a carboxyl-terminal truncation of glycoprotein E is defective in anterograde neuronal transport in rabbits and calves
WO2002072802A3 (en) Live attenuated strains of prrs virus
WHISTLER et al. Generation of defective interfering particles by two vaccine strains of measles virus
WO2002009750A3 (en) Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene
Tadese et al. Detection of specific reticuloendotheliosis virus sequence and protein from REV-integrated fowlpox virus strains
EP0507179A3 (en) Equine herpes viruses (ehv) containing foreign dna, process for their preparation and their use as vaccines
HUP9901005A2 (en) Glycoprotein b of the rfhv/kshv subfamily of herpes viruses
von Einem et al. The truncated form of glycoprotein gp2 of equine herpesvirus 1 (EHV-1) vaccine strain KyA is not functionally equivalent to full-length gp2 encoded by EHV-1 wild-type strain RacL11
CA2412075A1 (en) Attenuated bovine respiratory syncytial virus
WO2002009749A3 (en) Respiratory syncytial virus vaccine
ATE223492T1 (en) MUTANTS OF THE INFECTIOUS BOvine RHINOTRACHEITIS VIRUS AND VACCINES
WO1999057284A3 (en) Attenuated influenza viruses
AU1521492A (en) Recombinant varicella-zoster virus and process for constructing same
EP0822980A4 (en) Recombinant infectious laryngotracheitis virus and uses thereof
Ur-Rehman et al. Locally prepared bovine herpesvirus 1 gE deleted vaccine induced immunogenicity in rabbits.
CA2198743A1 (en) Feline infectious peritonitis vaccine
Ostertag-Hill et al. Differentiation of BHV-1 isolates from vaccine virus by high-resolution melting analysis
WO2002047720A3 (en) Treatment and prevention of ebv infection and ebv-associated disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP MX NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001282997

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001961753

Country of ref document: EP

Ref document number: 523772

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2417340

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/000823

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2001961753

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 523772

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 523772

Country of ref document: NZ

WWR Wipo information: refused in national office

Ref document number: 2001961753

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001961753

Country of ref document: EP